Tests banding of esophageal varices in liver cancer patients receiving atezolizumab and bevacizumab
Tests band ligation of small varices in adults with liver cancer receiving atezolizumab and bevacizumab.
Plain-language title generated from the registry record
Registry title: Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
Key facts
- Where
- Tanta, EgyptSee the site
Where in Egypt
- Tanta University HospitalsTanta, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT06961526
- Record updated
- 8 May 2025
- Original description
The goal of this prospective cohort study is to evaluate the progression of esophagogastric varices in patients treated with atezolizumab-bevacizumab. Assess the efficacy of primary prophylaxis of small esophageal varices with no risky signs and shortening endoscopic follow-up time intervals to reduce the risk of variceal hemorrhage.Read full original descriptionShow less
Primary Prophylaxis of Esophageal Varices in Patients Treated With Atezolizumab and Bevacizumab for Advanced Hepatocellular Carcinoma.
The goal of this prospective cohort study is to evaluate the progression of esophagogastric varices in patients treated with atezolizumab-bevacizumab. Assess the efficacy of primary prophylaxis of small esophageal varices with no risky signs and shortening endoscopic follow-up time intervals to reduce the risk of variceal hemorrhage.
Researchers will assess the progression of esophageal varices (EVs) with no bleeding stigmata in patients treated with atezolizumab-bevacizumab therapy at 3, 6, 9, and 12 months with endoscopic examination. Evaluate the effect of shortening the endoscopic follow-up intervals to reduce the risk of variceal bleeding in patients treated with atezolizumab-bevacizumab therapy. Researchers will also assess the efficacy of variceal band ligation in small varices without bleeding stigmata before starting atezolizumab-bevacizumab therapy to reduce the progression of EVs.
Participants will undergo history-taking, clinical examination, laboratory investigations, Triphasic CT abdomen with contrast or MRI (for evaluation of tumor site, size and number), abdominal ultrasonography, and upper endoscopy (within 6 months before beginning of systemic therapy and followed up after 3, 6, 9, and 12 months).
Inclusion: Patients with confirmed advanced HCC (Diagnosed by two imaging modalities or liver biopsy) eligible for atezolizumab-bevacizumab therapy; Patients with preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis); Patients with performance status ≤2 at staging work-up; Patients with no or grade 1 non-risky esophageal varices on pretreatment endoscopic examination.
Exclusion: Vascular disorders and arterial hypertension; Severe autoimmune disorders; Child-Pugh class C patients; Patients with performance status >2 at staging work-up; Patients who lost follow-up; Pregnant or breastfeeding women; Unwilling to participate in our study.